title: Changes in Weight and Body Composition Among Women With Breast Cancer During and After Adjuvant Treatment: A Prospective Follow-up Study.
abstract: Antineoplastic adjuvant treatment for breast cancer can cause changes in women's weight and body composition and influence their general health and survival.
  
  
  
  The aim of this study is to investigate the extent and patterns of change in weight and body composition after current standard adjuvant antineoplastic treatment for breast cancer.
  
  
  
  Data on weight and body composition from 95 women with breast cancer Stage I to III were obtained during 18 months on a bioelectric impedance analyzer. Changes and odds ratio (OR) were calculated by a linear mixed model and logistic regression.
  
  
  
  At 18 months, there was an increase in weight of 0.9 kg (95% confidence interval [CI], 0.3-1.5; P = .003) and an average positive association of 0.35 kg/cm increased waist circumference (95% CI, 0.29-0.42 kg; P < .0001). Relative weight changes ranged from -12.7% to 20.5%. Weight gains related to increased body fat were observed mainly in premenopausal women receiving chemotherapy (1.4 kg; 95% CI, 0.4-2.4; P = .007). For menopausal status, OR was 2.9 (95% CI, 1.14-7.1; P = .025), and for chemotherapy, OR was 2.6 (95% CI, 1.03-6.41; P = .043). The OR for weight loss in Stage III breast cancer was 12.5 (95% CI, 1.21-128.84; P = .034) and 4.3 (CI, 1.07-17.24; P = .40) for comorbidity.
  
  
  
  Results demonstrate that weight changes in a pooled sample are overestimated. However, premenopausal women receiving anthracycline-based chemotherapy show a tendency toward a body composition with increasing fat mass.
  
  
  
  A scheduled assessment of changes in weight and body composition is relevant at 18 months after treatment. To compare future studies, common measuring and cutoff points are needed.
authors.affiliation: Author Affiliations: Department of Oncology, Aalborg University Hospital, Denmark (Ms Pedersen and Drs Carus and Falkmer); Unit of Clincal Biostatistics and Bioinformatics, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Denmark (Ms Bendtsen); Clinical Nursing research Unit, Aalborg University Hospital, Denmark (Dr Groenkjaer); Institute of Public Health, Section of Nursing, Aarhus University, Denmark, and University College Diakonova, Oslo, Norway (Dr Delmar); and Clinical Nutrition Unit, Salgrenska University Hospital, Goethenburg, Sweden (Dr Boseaus).
authors.forename: Birgith
authors.initials: B
authors.lastname: Pedersen
authors.forename: Charlotte
authors.initials: C
authors.lastname: Delmar
authors.forename: Mette Dahl
authors.initials: MD
authors.lastname: Bendtsen
authors.forename: Ingvar
authors.initials: I
authors.lastname: Bosaeus
authors.forename: Andreas
authors.initials: A
authors.lastname: Carus
authors.forename: Ursula
authors.initials: U
authors.lastname: Falkmer
authors.forename: Mette
authors.initials: M
authors.lastname: Groenkjaer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001823:Body Composition; D001835:Body Weight; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D017697:Premenopause; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents